PolyNovo Highlights Continued Revenue Growth and FDA-Cleared NovoSorb MTX

PolyNovo’s H1 FY26 Investor Call: A Window into Growth

PolyNovo Limited (ASX: PNV), a leader in medical technology focused on complex wound management, has made available the recording of its H1 FY26 investor call. This comprehensive briefing offers shareholders and interested parties insights into the company’s operational and financial progress, featuring updates from the Chair and CEO, detailed financial results, and a Q&A session.

Driving Innovation with NovoSorb Technology

At the core of PolyNovo’s growth story is its proprietary NovoSorb polymer platform. This biodegradable polymer is engineered to support tissue regeneration, offering unique advantages such as excellent biocompatibility and a programmable bio-resorption profile. The technology’s versatility allows it to be manufactured in various forms including films, fibres, foams, and coatings, enabling a broad range of medical applications.

Two flagship products exemplify this innovation: NovoSorb BTM, a synthetic dermal scaffold designed to regenerate dermis lost through trauma or surgery, and NovoSorb MTX, a fully synthetic dermal matrix that has gained FDA clearance and is rapidly being adopted by surgeons. The latter’s design responds directly to clinical demand for a dermal substitute without a sealing membrane, positioning it as a key growth driver.

Global Reach and Market Leadership

PolyNovo’s footprint extends beyond its Melbourne headquarters to significant international markets including the United States, United Kingdom, India, Hong Kong, and Singapore. Supported by distributor partnerships, the company has established market leadership in several geographies, underpinned by clinical adoption and positive patient outcomes.

While the announcement does not disclose specific financial figures, it underscores continued revenue growth and profitability, reflecting the commercial traction of its advanced wound care products. The webcast recording provides a valuable resource for investors seeking deeper understanding of PolyNovo’s strategic direction and financial health.

Looking Ahead

PolyNovo’s achievements to date, including regulatory clearances and expanding clinical evidence, set a strong foundation for sustained growth. The company’s ability to leverage its NovoSorb technology platform to develop new products and enter new markets will be critical in maintaining momentum.